Danaher reports 8.5% revenue growth and raises 2026 earnings guidance

Danaher reported third-quarter 2026 revenue of $6.6 billion for the period ended September 25, up 8.5% year over year, while net earnings rose 34.5% to $1.2 billion, or $1.71 per diluted share; adjusted diluted EPS increased 11.5% to $2.11. Operating cash flow was $1.9 billion and free cash flow was $1.6 billion, and Danaher raised its full-year 2026 adjusted EPS guidance to $8.57-$8.62 from $8.45-$8.60; it expects fourth-quarter core revenue growth excluding respiratory testing of 4%-5%, with respiratory revenue a 150-basis-point headwind.